Skip to content

Efficacy and safety of olezarsen in patients with vs without baseline fibrate use.

Aug 2026 · Journal of Clinical Lipidology · 1 citation · 18 references
Medicine

TL;DR

Olezarsen reduced triglycerides across the hypertriglyceridemia spectrum, with greater effects in patients on background fibrates, particularly with diabetes, to support potential complementary mechanisms and further investigation of concomitant triglyceride-reducing therapy.

Abstract

Background

Hypertriglyceridemia is associated with increased atherosclerotic cardiovascular disease and pancreatitis risk, yet durable triglyceride reduction remains challenging. Olezarsen, an antisense oligonucleotide targeting APOC3, substantially reduced triglycerides in phase 3 trials. Fibrates lower triglycerides through complementary lipoprotein lipase and apolipoprotein C-III (APOC3) pathways. Whether fibrate therapy modifies olezarsen's effects is unknown.

Objective

To evaluate the effects of olezarsen on triglycerides and other lipid parameters according to baseline fibrate use.

Methods

This prespecified secondary analysis included 3 phase 3, randomized, double-blind, placebo-controlled trials. Adults with severe hypertriglyceridemia (triglycerides ≥500 mg/dL; CORE-TIMI 72a/CORE2-TIMI 72b, pooled) or moderate hypertriglyceridemia with elevated cardiovascular risk (triglycerides 150-499 mg/dL; Essence-TIMI 73b) were randomized to monthly olezarsen (50 or 80 mg) or placebo. Placebo-adjusted triglyceride changes at 6 and 12 months were estimated using adjusted analysis-of-covariance models with treatment-by-fibrate interaction terms. Secondary endpoints included levels of APOC3 and lipid parameters, with subgroup analyses by diabetes.

Results

Among 1061 patients with severe and 1349 patients with moderate hypertriglyceridemia, 64% and 23% used fibrates at baseline. Olezarsen reduced triglycerides across all groups, with greater effects in fibrate users. In severe hypertriglyceridemia, placebo-adjusted triglyceride changes for fibrate users vs nonusers were -68.0% (95% CI: -75.2, -60.8) vs -53.2% (-62.9, -43.5) at 6 months (interaction P [Pint] = .02) and -66.3% (-73.4, -59.1) vs -48.4% (-58.2, -38.7) at 12 months (Pint = .004). In moderate hypertriglyceridemia, changes were -71.1% (-84.1, -58.1) vs -57.4% (-64.9, -49.9) at 6 months (Pint = .07) and -76.0% (-95.8, -56.2) vs -49.5% (-61.3, -37.8) at 12 months (Pint = .02). Similar patterns were observed for APOC3 and select atherogenic lipoproteins. Interactions were more consistently observed among patients with diabetes. Safety was similar across groups.

Conclusion

Olezarsen reduced triglycerides across the hypertriglyceridemia spectrum, with greater effects in patients on background fibrates, particularly with diabetes. Findings support potential complementary mechanisms and further investigation of concomitant triglyceride-reducing therapy.

View source

Similar papers

Review Sep 2026

Efficacy and Safety of Ongericimab in Patients With Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With GRADE Assessment.

Ongericimab is a humanized monoclonal antibody against proprotein convertase subtilisin/kexin type 9 that reduces LDL-C and increases apolipoprotein A1 and high-density lipoprotein cholesterol and increased apolipoprotein A1 and high-density lipoprotein cholesterol (all P < 0.0001).

Ahmed Talkhan, M. Elkasaby, Ahmed S. A. Osman et al. · 0 citations
Open access Aug 2026

Retatrutide‐Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes

To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D).

G. Ruotolo, C. Harris, Yanzhu Lin et al. · 0 citations
Open access Sep 2026

Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes.

In this indirect treatment comparison for obesity treatment in adults without T2D, with obesity, or overweight with ≥1 ORC, compared with semaglutide, tirzepatide 10 or 15’mg was associated with improvements in weight reduction, body composition and several cardiometabolic risk factors and generally similar safety prof...

A. Ciudin, Erin Johansson, S. Zimner-Rapuch et al. · 0 citations
Open access Aug 2026

Evaluation of relative safety and therapeutic efficacy of antihyperlipidemic drug regimens used alone or in combination in cardiovascular disease: randomized controlled study

Moderate-intensity rosuvastatin combined with ezetimibe achieved lipid-lowering efficacy comparable to high-intensity rosuvastatin while producing lower relative increases in liver enzymes over 24 weeks, suggesting that combination therapy represents a reasonable therapeutic alternative for selected patients requiring...

Nourhan K. Elsaeed, Refaat H. Abdelmoety, Ehab Elyamani et al. · 0 citations
Open access Sep 2026

Comparative effects of enavogliflozin versus dapagliflozin on adipokines in patients with type 2 diabetes mellitus: a pooled analysis of two randomized controlled trials

Enavogliflozin showed a greater reduction in leptin than dapagliflozin, which persisted after adjustment for weight change, and changes in leptin correlated positively with changes in insulin, C-peptide, and HOMA-IR.

Y. Lyu, Kyung-Soo Kim, H. Lee et al. · 0 citations
Review Open access Aug 2026

Efficacy and Safety of Oral Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analyses

Overall, oral semaglutide appears to produce clinically meaningful reductions in body weight and BMI in adults without diabetes, while maintaining a safety profile consistent with other GLP-1 receptor agonists.

A. M. García-Sierra, J. C. Martínez, Felipe Girón Arango et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.